ABSTRACT
Integrin alphavbeta3 plays a pivotale role in tumor angiogenesis and is a receptor for the extracellular matrix proteins with the exposed arginine-glysine-aspartic acid (RGD) tripeptide sequence (e.g. vitronectin, fibronectin). Alphavbeta3 is overexpressed on activated endothelial cells during tumor-induced angiogenesis, whereas it is absent on quiescent endothelial cells and normal tissues. Furthermore, alphavbeta3 is expressed on various tumor cell lines. Due to this restricted expression of alphavbeta3 in tumors, alphavbeta3 is considered a suitable receptor for tumor targeting. In the past decade, several RGD-containing peptide antagonists have been evaluated for monitoring alphavbeta3 expression using SPECT, PET, MRI, OI and US. Molecular imaging tracers for this integrin receptor could be used to noninvasively visualize alphavbeta3 expression in tumors. Noninvasive determination of alphavbeta3 expression potentially can be used to monitor treatment response to antiangiogenic drugs or even to select patients likely to respond to treatment with antiangiogenic drugs. In this review a brief overview on the currently used RGD-containing peptides as imaging probes for noninvasive visualization of alphavbeta3 expression using PET, SPECT, MRI, OI and US is given.
INTRODUCTION
Integrins are a family of transmembrane glycoproteins that function in cellular adhesion, migration and signal transduction. The term "integrin" was derived from the ability of these proteins to link the extracellular matrix (ECM) proteins with the intracellular cytoskeleton (1). Each member of this family consists of two noncovalently bound transmembrane polypeptide subunits, alpha and beta. Integrins have a large extracellular domain which binds extracellular ligands, a transmembrane domain, and a relatively small intracellular domain responsible for interaction with the cytoskeleton and intracellular signaling pathways. To date, 18 alpha-and 8 beta-subunits have been identified, which associate selectively to form at least 24 different integrins. The unique combinations of alpha-and beta-subunits determine which ECM ligands are recognized by a cell. Binding of ECM ligands to integrins triggers interactions between several signaling molecules in close vicinity to the extracellular and cytoplasmic regions of the integrin receptor (2, 3). Integrin-mediated cell adhesion may affect the cell cycle kinetics, or may cause anchorage-dependent cell death or anoikis (4, 5).
The alpha-subunit alphav can associate with various integrin beta-subunits. At present there are at least three distinct beta-subunits which associate with the alphav-subunit, namely, beta1, beta3, and beta5. The integrin alphavbeta3, also referred to as the vitronectin receptor, binds to a variety of extracellular matrix proteins, including vitronectin, fibrinogen, laminin, collagen, von Willebrand Factor and osteopontin through their exposed arginine-glycine-aspartic acid (RGD) amino acid sequence (6). Integrin alphavbeta3 is expressed on a variety of cell types, including osteoclasts, vascular smooth muscle cells, and endothelial cells. In addition, alphavbeta3 integrin is expressed on the cell membrane of various tumor cell types such as ovarian cancer, neuroblastoma, breast cancer, melanoma, and others. Furthermore, for growth beyond the size of 1-2 mm in diameter, tumors require the formation of new blood vessels. The formation of new blood vessels from pre-existing ones (angiogenesis) into an avascular tissue, is often triggered by an insufficient nutrient supply resulting in hypoxic cells (7). Binding of the hypoxia inducible factor (HIF-1alpha) to the hypoxia response element activates expression of vascular endothelial growth vector (VEGF), which plays a major role in angiogenesis. Integrin alphavbeta3 is minimally expressed on normal quiescent endothelial cells, but significantly upregulated on activated endothelial cells during angiogenesis (8). Alphavbeta3 integrin expressed on endothelial cells modulate cell migration and survival during angiogenesis, while alphavbeta3 integrin expressed on carcinoma cells potentiate metastasis by facilitating invasion and movement across blood vessels.
Molecular imaging tracers for this integrin receptor could be used to noninvasively visualize alphavbeta3 expression in tumors. Noninvasive determination of alphavbeta3 expression potentially can be used to monitor treatment response to antiangiogenic drugs or even to select patients likely to respond to treatment with antiangiogenic drugs.
This review tries to give a brief overview on the currently used RGD-containing peptides as imaging probes for noninvasive visualization of alphavbeta3 expression using positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), optical imaging (OI) and ultrasound (US).
RGD-CONTAINING PEPTIDES AS IMAGING PROBES FOR ALPHAVBETA3 EXPRESSION

Nuclear imaging
During the last decades, the application of radiolabeled peptides and proteins for diagnostic imaging and therapeutic treatment has rapidly gained importance in nuclear medicine.
Apart from planar imaging, SPECT and PET are the two main imaging modalities in nuclear medicine. SPECT imaging is much more widely available than PET imaging and the radionuclides used for SPECT are easier to prepare and usually have a longer half-life than those used for PET. Commonly used gamma emitters are:
123 I (E max 529 keV, t 1/2 13.0 h), 111 In (E max 245 keV, t 1/2 67.2 h), and 99m Tc (E max 141 keV, t 1/2 6.02 h). Compared to SPECT, PET has a higher spatial resolution and the possibility to more accurately quantitate in vivo the concentration of a tracer labeled with a positron emitting radionuclide for clinical application, such as 18 F (E max 635 keV, t 1/2 1.83 h), 68 Ga (E max 1.90 MeV, t 1/2 68.1 min), 64 Cu (657 keV, t 1/2 12.7 h), and for experimental use 124 I (E max 2.13 MeV; 1.53 MeV; 808 keV, t 1/2 4.18 days).
PET is independent of the location depth of the reporter probe of interest and is able to detect picomolar concentrations of tracer (9). This high sensitivity of PET is only reached by optical imaging techniques, but not by MRI, computed tomography (CT) or ultrasound. In addition, compared to MRI and conventional optical imaging techniques, PET has the advantage that it can be quantitative. Though, with the introduction of fluorescence mediated tomography (FMT), quantitative measurements are also possible with OI techniques (10). However, the spatial resolution of PET and SPECT scanners used for clinical applications is lower compared to the spatial resolution of clinical MRI, CT and US scanners.
Monomeric radiolabeled RGD peptides
Integrin alphavbeta3 binds extracellular matrix proteins (e.g. vitronectin, fibrinogen, laminin, collagen) through exposed tripeptide arginine-glycine-aspartic acid (RGD) amino acid moieties (11). The potential of RGDcontaining peptides to serve as vehicles for targeting tumors with radionuclides has been investigated by several groups. It was found that the cyclic derivative cyclo(Arg-Gly-Asp-DPhe-Val) was a 100-fold better inhibitor of cell adhesion to vitronectin when compared to the linear variant, with an IC 50 value in the lower nanomolar range (12, 13). It was shown that besides the essential RGD sequence, a hydrophobic amino acid in position 4 increases the affinity for alphavbeta3 (14). Based on this finding Haubner and coworkers designed five peptides that could be radioiodinated by introducing a tyrosine residue. Two of these peptides, cyclo(Arg-Gly-Asp-DTyr-Val) and cyclo(Arg-Gly-Asp-D-Phe-Tyr) (designated as P1 and P4, respectively) were studied in vivo (15). The biodistribution of the radioiodinated peptides was studied in nude mice with various tumors (M21 melanoma, MaCaF mammary carcinoma, and osteocarcoma). The peptides rapidly cleared from the blood; blood levels were lower than 1 %ID/g as early as 10 min postinjection (p.i.). In mice with M21 melanoma, tumor uptake peaked at 10 min p.i. (1.12 ± 0.98 %ID/g) and decreased to 0.12 ± 0.04 %ID/g at 2 h p.i.. However, both peptides cleared via the hepatobiliary route and revealed relatively high hepatic uptake, especially at early time points (~5 %ID/g, 1 h p.i.), which is unfavorable for patient studies. It has been demonstrated that introduction of sugar moieties resulted in reduced liver uptake and increased tumor accumulation of a variety of somatostatin receptor (SSTR)-antagonists (16, 17, 18, 19) . Therefore, to improve the pharmacokinetics of the first generation radiohalogenated RGD peptides, sugar amino acids were introduced. A glucose-based sugar amino acid (SAA1) was conjugated to the epsilon-amino function of lysine in the The hydrophilicity of peptides can also be enhanced by linking them to polyethylene glycol (PEG) chains, an approach called PEGylation. Chen and coworkers coupled PEG-moieties to RGD-containing peptides. Radioiodinated, 18 F-and 64 Cu-labeled derivatives were studied and demonstrated different effects of PEGylation on the pharmacokinetics, tumor uptake and retention of the RGD peptides. This could be due to the nature of the lead structure and the size of the PEG-moiety. For example, 125 I-RGD-mPEG (mPEG MW = 2,000) demonstrated higher activity concentration in liver and intestine compared to 125 I-RGD. In addition, the PEGylated analog showed faster blood clearance, lower uptake, but improved tumor retention compared to 125 I-RGD (25) . In contrast, the PEGylated RGD peptide 64 Cu-DOTA-PEG-RGD (PEG MW = 3,400) revealed lower uptake in liver and intestine with no effect on tumor uptake and retention compared to 64 Cu-DOTA-RGD (26) . In an experimental comparison, [ 18 F]FB-PEG-RGD (PEG MW = 3,400) had significantly improved tumor retention relative to [ 18 F]FB-RGD without compromising hepatic and renal clearance of activity (27) .
Recently, a 99m Tc-labeled RGD-containing peptide (NC100692) was evaluated in ischemic models and showed high uptake in areas of neovascularization with alphavbeta3 integrin overexpression (28) . Binding of NC100692 has been confirmed to be localized on endothelial cells in the regions of angiogenesis (29). Subsequently, a clinical study was performed to provide an initial indication of the efficacy and safety of imaging malignant breast tumors using 99m Tc-NC100692 (see "Translation into the clinic" section).
RGD-multimers
Multimers were developed to address the question of multimeric integrin binding by "poly-potent" ligands, and to initiate and target integrin clusters with noncarrier added (n.c.a.) radiopharmaceuticals (30, 31). The above mentioned alphavbeta3-selective peptides cyclo (-RGDfK-) or cyclo(-RGDfE-) were linked to polyethylenglycol (PEG) amino acid and other spacers (32, 33, 34). Monomeric units were bridged by lysine or a lysine tree to form dimeric, tetrameric and octameric RGDoligomers in a well-controlled, defined and characterized manner. The final 18 F-labeling step was carried out by oxime ligation, e.g. using 4-[
18 F]fluorobenzaldehyde. Comparison of the IC 50 of cyclo(-RGDfK-) and cyclo(-RGDfE-) containing monomers, dimers, tetramers and octamers for vitronection binding to alphavbeta3 revealed significantly increased affinity in the series monomer < dimer < tetramer < octamer. For example, the alphavbeta3-affinities of the cyclo(-RGDfE-)-mono-, di-and tetramer containing heptaethylenglycol spacer units were increased by a factor of ten with each duplication of binding units (IC 50 = 20, 3.0 and 0.2 nM, respectively for the mono-, diand tetramer). In contrast, the affinity of reference and control peptides carrying only one cyclo(-RGDfK-)-(or cyclo(-RGDfE-)-peptide, but otherwise non-binding cyclo(-RADfK-)-or cyclo(-RADfE-)-sequences, respectively, was lower or similar to that of the corresponding monomers. Together, these experiments clearly demonstrate the "multimer effect" in vitro with similar molecular structures, which is independent of differences in charge, size or shape. These data were also confirmed in vivo in M21-melanoma-tumor-bearing-mice (32). Tumor uptake increased in the series monomer < dimer ≈ tetramer, but due to lower activity accumulation of the tetramer in all other tissues compared to the dimer, tumor-to-organ-ratios were highest for the 18 F-labeled RGD-tetramer, leading to a significant improved imaging (Figure 2 ).
In a study by Chen and coworkers, the dimeric cyclic RGD peptide E(c(RGDyK)) 2 was labeled with 18 F by using a prosthetic 4-[
18 F]fluorobenzoyl moiety to the amino group of the glutamate (35) . The resulting [
18 F]FB-E(c(RGDyK)) 2 was obtained with high specific activity (200-250 GBq/micromol at the end of synthesis). In mice with subcutaneously growing U87MG glioblastoma, the dimeric RGD peptide demonstrated significantly higher tumor uptake and prolonged tumor retention in comparison with its monomeric analog [
18 F]FB-c(RGDyK). In addition, the dimeric peptide had a predominant renal excretion, whereas the monomeric analog was excreted preliminary through the biliary route.
The concept of multimerization has also been investigated with other RGD-ligand systems, such as 64 Cuand 68 Ga-labeled peptide dimers, tetramers, and even octamers (36, 37, 38, 39, 40, 41, 42) . Compared with DOTA-RGD tetramer, DOTA-RGD octamer further increased the integrin affinity by a factor of 3 (IC 50 = 2.8 ± 0.4 and 1.1 ± 0.2 nM, respectively). In vivo microPET imaging showed that [ 64 Cu]DOTA-RGD octamer had slightly higher initial tumor uptake and longer tumor retention. However, the octamer exhibited significantly higher renal uptake in both subcutaneous U87MG xenografts and mammary adenocarcinoma-bearing c-neu oncomice compared with the tetramer, which resulted from integrin alphavbeta3 expression in kidneys, increased alphavbeta3-binding affinity and the presence of more positively charged amino acid residues (36) . Overall, the multimerisation approach leads to increased binding affinity and tumor uptake as well as retention and can improve the pharmacokinetics of peptide-based tracers (for an overview see (43)).
Magnetic resonance imaging
MRI offers good depth penetration and its resolution is usually higher than that of clinical PET scanners although this depends on the exact protocol applied. MRI is widely used clinically to assess tumor growth and for response evaluation. Anatomical information can be coregistered with functional and molecular information within a single imaging method. A further advantage compared to radiotracer techniques is that MRI does not use ionizing radiation and generally is more widely available than PET. A major disadvantage of MRI compared to radiotracer techniques is its lower sensitivity for the detection of targeted agents. However, the problem of limited sensitivity might be overcome in the future by signal amplification strategies that generate higher target-to-background contrast (44) .
Imaging of alphavbeta3 expression has been achieved by using Gd 3+ -containing paramagnetic liposomes with a diameter of 300 -350 nm and the alphavbeta3 specific antibody LM609 as a ligand (45) . Peptidomimetic integrin alphavbeta3 antagonist conjugated magnetic nanoparticles were also used for MRI in a Vx-2 squamous cell carcinoma model with a common clinical MRI scanner at 1.5 T (46). The targeted nanoparticles increased the MR signal significantly in the periphery of the tumor at 2 h p.i.. Moreover, nude mice with human melanoma tumor xenografts were successfully imaged using alphavbeta3 integrin-targeted paramagnetic nanoparticles (47) . The authors claimed that very small regions of about 30 mm 3 of angiogenesis associated with melanoma tumor xenografts were visualized, which may enable characterizing and staging of early melanoma in a clinical setting.
However, Gd 3+ for enhancing the T1 contrast can only be reliably detected at millimolar levels. Superparamagnetic iron oxide (SPIO) nanoparticles can be detected at a much lower concentration because of the high susceptibility induced by this particles which leads to a decrease of the signal in T2 and especially T2* weighted sequences ("negative contrast") (48) . In a recent study, alphavbeta3 integrin-targeted ultrasmall SPIO (USPIO) nanoparticles were used for noninvasive differentiation of tumors with high and lower area fractions of alphavbeta3-positive tumor vessels (49) . After RGD-USPIO injection, T2*-weighted MRI identified the heterogeneous distribution of alphavbeta3-positive tumor vessels by an irregular signal intensity decrease, whereas the signal intensity decreased more homogeneously in the control tumor with predominantly small and uniformly distributed vessels.
Imaging based on T2w sequences is also possible with iron-oxide based dual modality nanoparticles, like RGD-CLIO-Cy5.5, which allow both for MRI and fluorescence imaging (50) . This approach combines the high sensitivity of optical imaging with the high spatial resolution of MRI. Our lab recently developed a bifunctional iron oxide (IO) nanoparticle probe for PET and MR imaging of tumor integrin alphavbeta3 expression. With a core size of 5-7 nm, Poly (aspartic acid) (PASP)-coated IO nanoparticles (PASP-IO) were coupled to cyclic RGD peptides and macrocyclic DOTA chelators to get a bifunctional probe -DOTA-IO-RGD conjugates. The probe bound specifically to integrin alphavbeta3 in vitro. Both microPET and T2-weighted MR imaging showed integrinspecific delivery of conjugated RGD-PASP-IO nanoparticles and prominent reticuloendothelial system (RES) uptake. This bifunctional imaging approach may allow for earlier tumor detection with a high degree of accuracy and provide further insight into the molecular mechanisms of cancer.
Ultrasound
Ultrasound has a high spatial resolution (50-500 micrometer) yet it also has disadvantages such as the relatively poor depth penetration (usually a few centimeters depending on the frequency used) and limited sensitivity. For integrin alphavbeta3 targeted contrast enhanced ultrasound ("CEU"), the shell surface of microbubbles has been conjugated with echistatin, a peptide derived from the venom of the viper Echis carinatus which bears the RGD motif (51) . Using gray-scale pulse-inversion techniques, tumor-blood volume determined by CEU increased by approximately 35% from day 14 to day 28, whereas microvascular blood velocity decreased, especially at the central portions of the tumors (52) . In another study, antihuman integrin alphavbeta3 antibody conjugated microbubbles and cyclic RGD peptide conjugated microbubbles have been prepared for in vitro ultrasonic analysis. Specific adhesion of these contrast agents to alphavbeta3-expressing cell monolayers was achieved in vitro and acoustic studies illustrated a backscatter amplitude increase from monolayers exposed to the targeted contrast agents of up to 13-fold (22 dB) relative to enhancement due to control bubbles (53) . Tartis et al. constructed drug delivery vehicles, referred to as acoustically active lipospheres (AALs), which are microbubbles surrounded by a shell of oil and lipid (54) . In a region limited to the focal area of ultrasound application, circulating AALs are deflected by radiation force to a vessel wall and can subsequently be fragmented. RGD peptide conjugated AAL shell showed an increase in in vitro binding by 26.5-fold over nontargeted agents. Toxicity assays demonstrate that paclitaxel-containing AALs exert a greater antiproliferative effect after insonation than free paclitaxel at an equivalent concentration. The combination of ultrasound and molecular targeting successfully delivered a model drug to the endothelium and interstitium of chorioallantoic membrane vasculature in vivo (54) .
Optical imaging of alphavbeta3 expression
Optical imaging and in particular, near-infrared fluorescence (NIRF) imaging, which makes use of photons emitted in the near-infrared and far red range, has the advantage of being relatively inexpensive, highly sensitive and noninvasive. Due to its limited depth penetration, it is mainly applied in preclinical animal studies and in superficial tissues or in combination with endoscopy. Nearinfrared light penetrates tissue sufficiently well to allow one to obtain low-resolution images of tissues to a depth of a few centimetres, and the regional concentration of hemoglobin and oxygen saturation can be calculated from the absorption of hemoglobin and deoxyhemoglobin. Limitations of OI include its limited depth penetration, the effects of blood absorption and autofluorescence. Moreover, conventional optical imaging does not allow for quantitative measurements. However, this has changed with the introduction of fluorescence mediated tomography (FMT), which allows for quantitative measurements of fluorochrome concentrations at different tissue depths (10). Fluorescence imaging has been used for retinal angiography, cardiovascular surgery, and gastrointestinal endoscopy using either indocyanine green, a clinically available contrast agent that fluoresces at near-infrared wavelengths, or autofluorescence. Indocyanine green has also been used to image angiogenic vasculature in breast tumors (55, 56) . In addition, a vast array of sensitive molecular imaging agents associated with angiogenesis specific targets has been developed for OI techniques, such as agents sensitive for matrix metalloproteases or alphavbeta3 (57) . The simplest technique is the use of cyanine dyes like Cy5.5 coupled to RGD peptides. This approach has been successfully used for imaging of U87MG tumor xenografts in mice using NIRF (58) . Analogous to the radiotracer approach, multimeric compounds like Cy5-RAFT-c (-RGDfK-)4 demonstrated increased binding affinity compared to the monomeric compound (59) . Finally, the use of FMT allows for quantification of fluorochrome concentrations in living subjects, therefore potentially allowing for quantification of alphavbeta3 expression by RGD-specific cyanine dyes. The principle of FMT using Cy5.5-RGD has recently been successfully demonstrated by the group of Bremer et al. (60) . This approach is therefore well suited for high throughput studies and a potential alternative to radiotracer studies in the preclinical setting.
Another strategy is to use quantum dots (QD) for OI. QDs are inorganic fluorescent semiconductor nanoparticles with many desirable optical properties for imaging applications, such as high quantum yields, high molar extinction coefficients, strong resistance to photobleaching and chemical degradation, continuous absorption spectra spanning the UV to NIR range and narrow emission spectra, typically 20-30 nm full width at half maximum (61, 62, 63) . Specific targeting can be achieved by attaching targeting ligands to the QD surface. However, significant limitations for in vivo imaging are the , open tip) . Note, the tracer accumulation in the urogenital tract due to predominantly renal tracer elimination, and to a lesser extent in the gallbladder, liver and spleen. Only low tracer uptake is notable in the residual organs and background. The corresponding CT scan shows the osseous metastasis in the scapula (B) and in the pelvis (C). relatively large overall size over 20 nm and the short circulation half-life of QD conjugates. NIRF imaging of integrin alphavbeta3 on the tumor vasculature has been reported using RGD peptide-conjugated QDs (64) . RGD peptides were conjugated to QD705 (emission maximum at 705 nm) and QD705-RGD exhibited in cell culture and ex vivo high affinity integrin alphavbeta3 specific binding. Tumor contrast was observed as early as 20 minutes after QD705-RGD injection and the fluorescence intensity in subcutaneous U87MG tumors reached maximum at 6 h p.i.. Spectral imaging techniques were used to better interpret the NIRF imaging result since significant background signal is usually observed for in vivo NIRF imaging because of tissue autofluorescence (65, 66) . The large size of QD705-RGD with ~ 20 nm in diameter prevented extravasation, which was confirmed by ex vivo immunofluorescence staining. Thus QD705-RGD mainly targeted integrin alphavbeta3 on the tumor vasculature instead of the tumor cells. The major limitations concerning a clinical translation of QDs are the short half-life, potential toxicity, and lack of quantification (61) . However, with the development of smaller, less toxic and multifunctional QDs, QD-based probes might be optimized with acceptable toxicity for clinical translation in the future (67, 68, 69) .
TRANSLATION INTO THE CLINIC
Up to now, the one of the few approaches of imaging alphavbeta3 expression which has made the transition from bench to bedside is the radiotracer approach. [ 18 F]Galacto-RGD was one of the first substances applied in patients and could successfully image alphavbeta3 expression in human tumors with good tumorto-background ratios (70) (Figure 3) . In all patients, rapid, predominantly renal tracer elimination was observed, resulting in low background activity in most regions of the body. The metabolic stability analyzed from blood samples was >96% intact tracer 120 min after tracer injection. Further biodistribution and dosimetry studies confirmed rapid clearance of [ 18 F]Galacto-RGD from the blood pool and primarily renal excretion (71) . The calculated effective dose found was approximately 19 microSv/MBq, which is (72) . Dynamic studies with tracer kinetic modelling were used to assess distribution volume (D v ) values, which are supposed to reflect the receptor concentration in the tissue. These were on average four times higher for tumor tissue than for muscle tissue, suggesting specific tracer binding (73) .
In the lesions, tracer uptake revealed great interindividual heterogeneity. Moreover, there was also a great intraindividual heterogeneity of tracer uptake in different tumor sites in one patient which suggests great diversity of alphavbeta3 expression. This also emphasizes the potential value of noninvasive techniques for selection of patients entering clinical trials with alphavbeta3-targeted therapies, who could be stratified according to individual integrin expression levels. For this purpose, a quantification of integrin expression would be necessary. Therefore we evaluated, if [ 18 F]Galacto-RGD uptake correlates with alphavbeta3 expression. 19 patients with solid tumors were examined with PET using [
18 F]Galacto-RGD before surgical removal of the lesions (74) . Tumor tissue sections from representative areas with low as well as high SUVs were collected and immunohistochemistry was performed. Intensity of staining and the microvessel density of alphavbeta3-positive vessels were determined and correlated with SUV and tumor-to-blood ratios (Figure 4 ). SUVs and tumor-to-blood ratios were found to correlate significantly with the intensity of immunohistochemical staining as well as with the microvessel density. As mentioned before, variation in tracer design is supposed to further improve the performance of alphavbeta3 imaging, e.g. using multimeric RGD peptides. Recently, the SPECT tracer [
99m Tc]NC100692 was introduced for imaging alphavbeta3 expression in patients with breast cancer. 19 of 22 tumors could be detected with this agent, which was safe and well tolerated by the patients (77) . This is in accordance with results obtained in breast cancer patients using [
18 F]Galacto-RGD PET, which showed heterogeneous uptake in primary as well as metastatic breast cancer (78) . It can be assumed, that agents for alphavbeta3 imaging will be commercially available in the near future enabling a more widely assessment of alphavbeta3-targeting probes in larger cohorts of patients.
CONCLUSIONS
Effective molecular imaging is not only depending on the continuing improvement in imaging equipment and technology, but is also strongly dependent on the availability of powerful probes with optimal in vivo biodistribution and imaging characteristics.
In the last few years, significant progress has been made on the development of tracers for the visualization of alphavbeta3-integrin expression by different modalities (e.g. nuclear imaging, magnetic resonance imaging, computed tomography, ultrasound) and a considerable variety of imaging techniques is now available on the preclinical level. Up to now only [
18 F]Galacto-RGD and [ 99m Tc]NC100692 have been transferred from bench to bedside and are currently assessed in clinical studies. These studies will provide new insight into the exact role of alphavbeta3 in the context of angiogenesis and tumor growth, and, together with ex vivo studies, will elucidate more information on the correlation of alphavbeta3 expression and other potential targets for antiangiogenic therapies, like MMP-and VEGF-/VEGF-receptor targeted drugs. In addition, newly developed high affinity binders to other integrin targets, such as alpha5beta1, and combinations of different imaging modalities might open further and eventually more selective routes to image angiogenic processes in animal models and patients with higher sensitivity and resolution. 
